Navigation Links
Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
Date:6/2/2011

NEW YORK, June 2, 2011 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development. Over the one-year review period (October 2009 through September 2010) over 400 late stage trials were initiated in the oncology sector, more than any other therapeutic area, according to Citeline analysts.

(Photo: http://photos.prnewswire.com/prnh/20110602/NE12798 )

Non-small cell lung cancer was the leading disease type, followed closely by breast cancer.  "Notably, trials enrolling multiple hematological cancers and multiple solid tumors came in third and sixth, respectively, among all oncology diseases," commented Dr. Fern Barkalow, Oncology Senior Analyst at Citeline. "These trials represented 10% of the total, which was almost double that of the prior year, suggesting an effort by industry to increase the likelihood of success."

Additional highlights from the Citeline analysis include the following:

  • Hodgkin's lymphoma and supportive care were the only indications that had more Phase III than Phase II trial starts.  
  • Both Merck KGaA and Boehringer Ingelheim had the highest proportions of Phase III to Phase II trial starts.
  • The majority of the trials initiated by the leading five companies evaluated targeted therapies, ranging from 63% to 97% of their trial starts.

Sector sees new entrants

The high level of activity in the oncology therapeutic area was further underlined by the significant number (133) of distinct companies sponsoring new trials in the 12-month period. This represents a 21% increase over the previous year.  Coincident with the increase in the number of sponsors, was a small decrease (16%) in the number of trial starts. "This could be the result of the apparent trend toward testing multiple cancer types together in one Phase II trial," noted Dr. Barkalow.

Twenty companies sponsored more than half of all the new trials during the year. Roche and Novartis initiated nearly twice as many as any other company, with Celgene, Lilly and Pfizer rounding out the top five.

ASCO meeting to highlight trials in progress

The upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to be held June 3 – 7, 2011 includes a poster session devoted to clinical trials in progress.  Nearly one-third of the abstracts scheduled for presentation in this session involve breast cancer. "This is a great opportunity to highlight features of ongoing trials, such as novel designs, and many of the trials reported in the Citeline trial starts analysis are likely to be included," commented Susan Danheiser, Citeline Senior Director for Oncology & Analytics. "This year again, Citeline will cover the clinical trials presented at the ASCO annual meeting, and it will be interesting to see how the landscape may change."  Multiple solid tumors and breast cancer were the leading areas of investigation for trials of all phases presented at last year's meeting, and Roche was the leading industry sponsor.

To download a full copy of the report, go to  www.citeline.com/preview/incite  

About Citeline

Citeline (www.citeline.com) provides the world's most comprehensive real-time R&D intelligence to the pharmaceutical industry, covering global clinical trial, investigator and drug intelligence. Our data is drawn from over 18,000 unique sources and analyzed by the industry's largest team – over 250 full-time expert analysts and editors.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
2. Reportlinker Adds Greece Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2017
3. Reportlinker Adds United Arab Emirates Neurology Devices Investment Opportunities, Analysis and Forecasts to 2017
4. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
5. CVS Caremark to Participate in the Citi Investment Research 2011 Global Consumer Conference
6. Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix
7. SC Launch Presents "Big Check" Investment to Two South Carolina Companies
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. Reportlinker Adds Medical Equipment Monthly Deals Analysis - M&A and Investment Trends, April 2011
10. MEDomics Announces a Growth Capital Investment from SpaGus Ventures LLC and Gary Augusta Joins MEDomics as Chief Operating Officer
11. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... MEMPHIS, Tenn. , Feb. 8, 2016  A ... Hospital scientists has discovered details of how the ... cells triggers a particularly aggressive form of acute lymphoblastic ... cells, in which genetic mutations trigger overproduction of immature ... --> The discoveries of the malfunction underlying the ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 /PRNewswire/ ... manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company designing ... disease, announced today agreements for the clinical supply of ... material at multiple sites, including Slough (UK), Visp (CH) ... --> Retinal diseases, such as age-related macular ...
Breaking Medicine Technology:
(Date:2/9/2016)... WI (PRWEB) , ... February 09, 2016 , ... ... Bergner’s, Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has ... College of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of ...
(Date:2/9/2016)... ... , ... Two renowned photographers, Robert Caplin (New York, NY) and Peter Lockley ... 14-19, 2016, hosted by Four Seasons Resort Maui at Wailea as part of the ... 2015, the Maui Photo Expedition workshop will once again consist of on-location ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain ... won. A team from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded ... delicate neural circuits of an intact rabbit brain for extremely long-term storage using ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert ... the beginning of a new charity campaign. As part of their ongoing community ... (CASA). In the belief that children deserve a voice, and in the spirit ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... and clothing, announced expansion into Canada to provide its range of unique and ... sales office in Quebec City that will provide bilingual customer service and marketing ...
Breaking Medicine News(10 mins):